Montag & Associates’s vTv Therapeutics VTVT Stock Holding History

Montag & Associates’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1	Closed	–	–	916
2021 Q3	$0	Buy	+1	New	+$75	﹤0.01%	898

Other funds holding VTVT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CIM

CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Montag & Associates's VTVT Position: Q4 2021 in Review

Montag & Associates sold out of vTv Therapeutics (VTVT) in Q4 2021, closing a stake of 1 share.

Montag & Associates first reported a position in VTVT in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 29 funds tracked by Wall St. Rank hold VTVT as of Q4 2021.

Montag & Associates reported no remaining vTv Therapeutics position as of Q4 2021 after selling out during the quarter.
Montag & Associates sold 1 vTv Therapeutics share in Q4 2021.
Montag & Associates first reported a position in vTv Therapeutics in Q3 2021 and held it in 1 quarter.
Montag & Associates's vTv Therapeutics position peaked at $0 in Q3 2021.
29 funds tracked by Wall St. Rank held vTv Therapeutics as of Q4 2021.

Based on Montag & Associates's 13F filing for Q4 2021, filed 9 Feb 2022.